National Institute on Drug Abuse; Notice of Closed Meetings, 44688-44689 [2024-11068]

Download as PDF 44688 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Notices The Office of the Assistant Secretary for Health, Office of Population Affairs (OPA) has modified its organizational structure. DATES: This new organizational structure was approved by the Secretary of Health and Human Services and takes effect on May 14, 2024. FOR FURTHER INFORMATION CONTACT: Jessica Swafford Marcella, Deputy Assistant Secretary for Population Affairs, Office of Population Affairs, Office of the Assistant Secretary for Health, Department of Health and Human Services at Jessica.marcella@ hhs.gov and 240–453–2800. SUPPLEMENTARY INFORMATION: Part A (Office of the Secretary, U.S. Department of Health and Human Services) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (60 FR 56605, dated November 9, 1995, and corrected at 75 FR 53304, August 31, 2010, amended at 82 FR 3005, dated January 10, 2017, and amended, most recently at 84 FR 14951, dated April 12, 2019) is amended to reflect the reorganization of the Office of Population Affairs (OPA), Office of the Assistant Secretary for Health (OASH). This reorganization will streamline operations and improve the efficiency and effectiveness of OPA. OPA is responsible for implementing and administering the Title X family planning program, managing the Office of Adolescent Health, which is headed by a director, and implementing and administering the Teen Pregnancy Prevention program and other adolescent health activities. The changes are as follows: I. Under Part C, section C–G, Organization, revise to organize OPA staff across six Divisions: Administration and Operations, Adolescent Health Programs, Clinical and Scientific Affairs, Policy and External Affairs, Research and Evaluation, and Title X Service Delivery. The Division of Administration and Operations will manage overall operations for OPA, including staff recruitment and retention, budgeting, training, and travel. The Division of Adolescent Health Programs will lead implementation of the Teen Pregnancy Prevention Program and other adolescent health programmatic activities. The Division of Clinical and Scientific Affairs will provide clinical and scientific expertise, consultation, and oversight for all OPA staff and activities. The Division of Policy and External Affairs will lead all policy and ddrumheller on DSK120RN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 18:13 May 20, 2024 Jkt 262001 communication activities for the office. The Division of Research and Evaluation will oversee data collection for OPA programs and will lead OPA’s research and evaluation activities. The Division of Title X Service Delivery will lead implementation of the Title X service delivery program. II. Delegations of Authority: All delegations and redelegations of authority made to officials and employees of affected organizational components will continue in them or their successors pending further redelegations, if allowed, provided they are consistent with this reorganization. (Authority: 44 U.S.C. 3101) Xavier Becerra, Secretary, U.S. Department of Health and Human Services. [FR Doc. 2024–11058 Filed 5–20–24; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Neurological Sciences Training Initial Review Group; NST–4 Study Section. Date: June 14, 2024. Time: 9:30 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Steven G Britt, MD, Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH/HHS NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301–480– 1953, steve.britt@nih.gov. Name of Committee: National Institute of Neurological Disorders and Stroke Special PO 00000 Frm 00064 Fmt 4703 Sfmt 4703 Emphasis Panel; Review of UE5 Training Applications. Date: July 12, 2024. Time: 2:30 p.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: William C. Benzing, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH/HHS NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301–496– 0660, benzingw@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS). Dated: May 15, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–11067 Filed 5–20–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; HEAL Initiative: Translating Research To Practice to End the Overdose Crisis. Date: June 27, 2024. Time: 10:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sheila Pirooznia, Ph.D., Scientific Review Officer, Division of Extramural Review, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC, E:\FR\FM\21MYN1.SGM 21MYN1 Federal Register / Vol. 89, No. 99 / Tuesday, May 21, 2024 / Notices 6021 Bethesda, MD 20892, (301) 496–9350, sheila.pirooznia@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Education Activities for Responsible Analyses of Complex, Large-Scale Data. Date: July 3, 2024. Time: 2:00 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Li Rebekah Feng, Ph.D., Scientific Review Officer, Division of Extramural Review, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC, 6021 Bethesda, MD 20892, (301) 827–7245, rebekah.feng@nih.gov. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Targeting Inflammasomes in HIV and Substance Use. Date: July 8, 2024. Time: 10:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Health, National Institute on Drug Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, Division of Extramural Research, Scientific Review Branch, National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC, 6021 Bethesda, MD 20892, (301) 594–9460, Soyoun.cho@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: May 15, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–11068 Filed 5–20–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES ddrumheller on DSK120RN23PROD with NOTICES1 National Institutes of Health National Institute of Neurological Disorders and Stroke; Amended Notice of Meetings Notice is hereby given of a change in the meetings of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, VCID Center Without Walls, June 11, 2024, 10:00 a.m. to 6:00 p.m.; BRAIN Initiative Connectivity across Scales Data VerDate Sep<11>2014 18:13 May 20, 2024 Jkt 262001 Coordinating Center (BRAIN CONNECTS DCC) (U24 Clinical Trial Not Allowed), June 13, 2024, 10:00 a.m. to 12:30 p.m.; and BRAIN Initiative: Research Resource Grants for Technology Integration and Dissemination (U24 Clinical Trial Not Allowed), June 20, 2024, 10:00 a.m. to 6:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 20852 which were published in the Federal Register on May 15, 2024, FR Doc. 2024–10633, 89 FR 42479. This notice is being amended to change the meeting formats of all three meetings from in-person to virtual. The dates and times of these meetings will remain the same. The meetings are closed to the public. Dated: May 15, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–11075 Filed 5–20–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Amended Notice of Meeting Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel, HEAL Initiative: Digital Biomarker, June 04, 2024, 10:00 a.m. to June 04, 2024, 06:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 20852 which was published in the Federal Register on May 13, 2024, FR Doc 2024–10379, 89 FR 41451. This notice is being amended to change the meeting format from inperson to virtual. The date and time will remain the same. The meeting is closed to the public. Dated: May 15, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–11074 Filed 5–20–24; 8:45 am] BILLING CODE 4140–01–P PO 00000 Frm 00065 Fmt 4703 Sfmt 4703 44689 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings of the National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Bioethics and Tech Development. Date: June 20, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Dem II, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20817 (Virtual Meeting). Contact Person: Debanjan Goswami, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Suite 200, Bethesda, MD 20892, (301) 827–4614, debanjan.goswami@ nih.gov. Name of Committee: National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Career Development Awards (Ks) and Conference support (R13) Review. Date: June 25, 2024. Time: 10:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Dem II, Suite 920, 6707 Democracy Blvd., Bethesda, MD 20817 (Virtual Meeting). Contact Person: Alexander O Komendantov, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Suite 959, Bethesda, MD 20892, (301) 496– 2763, alexander.komendantov@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health.) E:\FR\FM\21MYN1.SGM 21MYN1

Agencies

[Federal Register Volume 89, Number 99 (Tuesday, May 21, 2024)]
[Notices]
[Pages 44688-44689]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-11068]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; HEAL Initiative: Translating Research To Practice to 
End the Overdose Crisis.
    Date: June 27, 2024.
    Time: 10:00 a.m. to 6:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sheila Pirooznia, Ph.D., Scientific Review 
Officer, Division of Extramural Review, Scientific Review Branch, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC,

[[Page 44689]]

6021 Bethesda, MD 20892, (301) 496-9350, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Education Activities for Responsible Analyses of 
Complex, Large-Scale Data.
    Date: July 3, 2024.
    Time: 2:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Li Rebekah Feng, Ph.D., Scientific Review 
Officer, Division of Extramural Review, Scientific Review Branch, 
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, 
MSC, 6021 Bethesda, MD 20892, (301) 827-7245, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Targeting Inflammasomes in HIV and Substance Use.
    Date: July 8, 2024.
    Time: 10:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Soyoun Cho, Ph.D., Scientific Review Officer, 
Division of Extramural Research, Scientific Review Branch, National 
Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC, 
6021 Bethesda, MD 20892, (301) 594-9460, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: May 15, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-11068 Filed 5-20-24; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.